Journal
CLINICS IN LIVER DISEASE
Volume 17, Issue 3, Pages 445-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.cld.2013.05.001
Keywords
Personalized medicine; PEG-IFN; Analogues; Cirrhosis; Fibrosis regression
Categories
Ask authors/readers for more resources
Chronic hepatitis B virus (HBV) infection, affecting approximately 350 to 400 million people worldwide, is associated with significant morbidity and mortality. Chronic hepatitis B remains a public health issue despite marked progress in public intervention programs. Individuals with chronic HBV infection have an increased risk for cirrhosis, decompensated liver disease, and hepatocellular carcinoma. The availability of safe and effective vaccines has reduced the burden of diseases. The choice of appropriate pharmacotherapy is critical in altering the course of the infection and reducing the costs associated with the management of chronic hepatitis B.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available